Assessment of fitness in patients with cystic fibrosis and mild lung disease

McLoughlin, P.; McKeogh, D.; Byrne, P.; Finlay, G.; Hayes, J.; FitzGerald, M. X.
May 1997
Thorax;May1997, Vol. 52 Issue 5, p425
Academic Journal
No abstract available.


Related Articles

  • Cystic fibrosis breath test spots deadly infection.  // GP: General Practitioner;10/28/2005, p4 

    This article informs that according to U.S. and German research, a breath test for patients with cystic fibrosis could show whether they have developed a potentially life-threatening lung infection. The study included 20 patients with mild-to-moderate cystic fibrosis and 23 healthy patients. The...

  • DISCOVERY AEROSOLIZED KL-4 SURFACTANT SELECTED FOR PHASE 2A.  // Biotech Business;Oct2008, Vol. 21 Issue 10, p6 

    The article reports that Discovery Laboratories, Inc. has announced that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF). This trial is designed to evaluate the safety and tolerance in patients with mild to...

  • Transplantacija pluća u bolesnika sa cističnom fibrozom. Tješić-Drinković, Dorian; Tješić-Drinković, Duška // Paediatria Croatica;Apr-Jun2015, Vol. 59 Issue 2, p81 

    The rate of lung transplantation, the most aggressive therapy available for end-stage lung disease, is increasing and cystic fibrosis is one of the most frequent indications for the procedure, both in children and adults. The burdens of comorbidities related to the underlying cystic fibrosis are...

  • Efficacy of Ivacaftor in a Child with Cystic Fibrosis, End-Stage Lung Disease, and Cepacia Syndrome. Castro-Elias, Walter A.; Singh, Shipra; Hiatt, Peter W.; Oermann, Christopher M.; Moore, Robert H. // Pediatric Allergy, Immunology & Pulmonology;Dec2012, Vol. 25 Issue 4, p231 

    Ivacaftor is a small-molecule potentiator of the cystic fibrosis (CF) transmembrane-conductance regulator and was recently approved for use in CF patients with at least one copy of the G551D mutation. Two clinical trials have proven its efficacy in CF patients 6 years of age and older with...

  • Cystic fibrosis -- economic analysis of the TIGER-1 study.  // PharmacoEconomics & Outcomes News;4/28/2012, Issue 652, p6 

    The article discusses research on the resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function, referencing a study by E. M. Dewitt and colleagues published in the March 2012 issue of "Value in Health."

  • Denufosol Starts 2nd Phase III CF Study.  // Bioworld Week;2/18/2008, Vol. 16 Issue 7, p4 

    The article reports that Inspire Pharmaceutical Inc. has started its second Phase III trial which assesses the efficacy of denufosol in treating cystic fibrosis in the U.S. It states that denufosol, a kind of P2Y2 receptor agonist, has been found in previous studies as an effective drug in the...

  • Cystic Fibrosis.  // Current Medical Literature: Respiratory Medicine;2007, Vol. 21 Issue 1, p8 

    The article presents abstracts of medical research related to cystic fibrosis. They include "Pneumothorax in cystic fibrosis: A retrospective case series," "Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data" and "Effect of allergic bronchopulmonary...

  • CITATIONS AND CLINICIANS' NOTES: CYSTIC FIBROSIS.  // Current Medical Literature: Respiratory Medicine;2004, Vol. 18 Issue 1, p26 

    Presents citations and clinicians' notes on studies on cystic fibrosis. "Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL," by N. Reinhardt, et al; "Composite spirometric-computed tomography outcome measure in early cystic fibrosis lung disease,"...

  • New Therapies in Cystic Fibrosis. Ratjen, Felix; Grasemann, Hartmut // Current Pharmaceutical Design;2/11/2012, Vol. 18 Issue 5, p614 

    Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected patients. Lung disease is the major contributor to morbidity and mortality in patients with cystic...

  • A Lipid Mediator Hepoxilin A3 Is a Natural Inducer of Neutrophil Extracellular Traps in Human Neutrophils. Douda, David N.; Grasemann, Hartmut; Pace-Asciak, Cecil; Palaniyar, Nades // Mediators of Inflammation;2/16/2015, Vol. 2015, p1 

    Pulmonary exacerbations in cystic fibrosis airways are accompanied by inflammation, neutrophilia, and mucous thickening. Cystic fibrosis sputum contains a large amount of uncleared DNA contributed by neutrophil extracellular trap (NET) formation from neutrophils. The exact mechanisms of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics